Loading…
Loading…
EQUITY / NASDAQ · XNCM
Inovio Pharmaceuticals Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗1.16 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 1.16 USD · Volume 2,918,784
21 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Revenue | 0 USD | 0 USD | — |
| Operating profit | -18,624,522 USD | -23,084,519 USD | — |
| Net income | -6,012,458 USD | -23,519,412 USD | — |
| Cash and cash equivalents | 31,526,164 USD | — | — |
| Total liabilities | 45,018,411 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 31,526,164 USD | — | — | 44,273,319 USD | 44,273,319 USD | 36,567,420 USD | — | — |
| Net incomeIncome statement | -6,012,458 USD | -25,695,256 USD | -19,682,798 USD | — | -84,945,901 USD | -45,496,672 USD | -88,710,781 USD | -23,519,412 USD |
| Operating profitIncome statement | -18,624,522 USD | -40,574,515 USD | — | — | -86,822,104 USD | -21,210,455 USD | -69,345,503 USD | -23,084,519 USD |
| RevenueIncome statement | 0 USD | 0 USD | — | — | 65,343 USD | 0 USD | 65,343 USD | 0 USD |
| Total assetsBalance sheet | 49,389,494 USD | — | — | 74,310,035 USD | 74,310,035 USD | 69,385,656 USD | — | — |
| Total equityBalance sheet | 4,371,083 USD | — | 6,067,882 USD | 24,096,276 USD | 24,096,276 USD | -7,719,977 USD | — | 28,530,905 USD |
| Total liabilitiesBalance sheet | 45,018,411 USD | — | — | 50,213,759 USD | 50,213,759 USD | 77,105,633 USD | — | — |
| Capital expendituresCash flow statement | — | 0 USD | — | — | 285,698 USD | — | 158,254 USD | — |
| Financing cash flowCash flow statement | — | 18,108,851 USD | — | — | 53,050,095 USD | — | 25,915,458 USD | — |
| Investing cash flowCash flow statement | — | 8,782,537 USD | — | — | 14,039,357 USD | — | 14,097,546 USD | — |
| Operating cash flowCash flow statement | — | -39,638,543 USD | — | — | -88,629,430 USD | — | -69,258,881 USD | — |
| Report source | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 08/12/2026 | Open report ↗ Published: 03/12/2026 | Open report ↗ Published: 11/10/2025 | Open report ↗ Published: 11/10/2025 | Open report ↗ Published: 08/12/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.